Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Use of Chymotrypsin in the Treatment of Dendritic Keratitis

The Use of Chymotrypsin in the Treatment of Dendritic Keratitis Abstract Every ophthalmologist is familiar with the typical clinical appearance of dendritic ulcer of the cornea. Since the first description of this virus infection of the cornea as a clinical entity by Horner1 in 1871, many forms of treatment have been tried. Among the therapeutic agents reported are alcohol, potassium iodide, hydrogen peroxide, silver nitrate, trichloracetic acid, epinephrine hydrochloride under a contact glass, alkalis, vaccination, curettage, paracentesis of the anterior chamber, ultraviolet light, x-rays, cobalt, strontium90, strong solution of iodine, and U.S.P. ether. Of all of the agents mentioned ether and strong solution of iodine have proved to be the most effective. However, both of these agents result in severe discomfort for the patient and they increase rather than decrease the possibility of corneal scarring. The therapeutic application of chymotrypsin became possible after its crystallization in 1933. It is a proteolytic enzyme extracted from mammalian pancreas and is now References 1. Horner, J. F.: Über Herpes Corneae , Klin. Mbl. Augenheilk. 9:321, 1871. 2. Miechowski, W. L., and Ercoli, N. J.: Studies on Proteolytic Enzymes: II. Trypsin and Chymotrypsin in Relation to Inflammatory Processes , J. Pharmacol. Exp. Ther. 116:43, 1956. 3. Sherry, S., et al.: The Enzymatic Dissolution of Experimental Arterial Thrombi in the Dog by Trypsin, Chymotrypsin and Plasminogen Activated , J. Clin. Invest. 33:1303, 1954.Crossref 4. Tagnon, H. J., et al.: Nature and Mechanism of Shock Produced by Intravenous Injection of Chymotrypsin , Amer. J. Physiol. 143:644, 1945. 5. Connell, J. E., and Rousselat, L. M.: The Use of Enzymatic Agents in the Débridement of Burn and Wound Sloughs , Surgery 30:43, 1951. 6. Jenkins, B. H.: Chymotrypsin, Its Varied Uses in Eye, Ear, Nose, Throat, and Related Conditions , Med. Times 87:1613, 1959. 7. Jenkins, B. H.: Use of Intramuscular Chymotrypsin in Ocular Conditions , J. Med. A. Georgia 45:431, 1956. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Ophthalmology American Medical Association

The Use of Chymotrypsin in the Treatment of Dendritic Keratitis

Archives of Ophthalmology , Volume 66 (1) – Jul 1, 1961

Loading next page...
 
/lp/american-medical-association/the-use-of-chymotrypsin-in-the-treatment-of-dendritic-keratitis-lQys2Cr4dz

References (7)

Publisher
American Medical Association
Copyright
Copyright © 1961 American Medical Association. All Rights Reserved.
ISSN
0003-9950
eISSN
1538-3687
DOI
10.1001/archopht.1961.00960010063012
Publisher site
See Article on Publisher Site

Abstract

Abstract Every ophthalmologist is familiar with the typical clinical appearance of dendritic ulcer of the cornea. Since the first description of this virus infection of the cornea as a clinical entity by Horner1 in 1871, many forms of treatment have been tried. Among the therapeutic agents reported are alcohol, potassium iodide, hydrogen peroxide, silver nitrate, trichloracetic acid, epinephrine hydrochloride under a contact glass, alkalis, vaccination, curettage, paracentesis of the anterior chamber, ultraviolet light, x-rays, cobalt, strontium90, strong solution of iodine, and U.S.P. ether. Of all of the agents mentioned ether and strong solution of iodine have proved to be the most effective. However, both of these agents result in severe discomfort for the patient and they increase rather than decrease the possibility of corneal scarring. The therapeutic application of chymotrypsin became possible after its crystallization in 1933. It is a proteolytic enzyme extracted from mammalian pancreas and is now References 1. Horner, J. F.: Über Herpes Corneae , Klin. Mbl. Augenheilk. 9:321, 1871. 2. Miechowski, W. L., and Ercoli, N. J.: Studies on Proteolytic Enzymes: II. Trypsin and Chymotrypsin in Relation to Inflammatory Processes , J. Pharmacol. Exp. Ther. 116:43, 1956. 3. Sherry, S., et al.: The Enzymatic Dissolution of Experimental Arterial Thrombi in the Dog by Trypsin, Chymotrypsin and Plasminogen Activated , J. Clin. Invest. 33:1303, 1954.Crossref 4. Tagnon, H. J., et al.: Nature and Mechanism of Shock Produced by Intravenous Injection of Chymotrypsin , Amer. J. Physiol. 143:644, 1945. 5. Connell, J. E., and Rousselat, L. M.: The Use of Enzymatic Agents in the Débridement of Burn and Wound Sloughs , Surgery 30:43, 1951. 6. Jenkins, B. H.: Chymotrypsin, Its Varied Uses in Eye, Ear, Nose, Throat, and Related Conditions , Med. Times 87:1613, 1959. 7. Jenkins, B. H.: Use of Intramuscular Chymotrypsin in Ocular Conditions , J. Med. A. Georgia 45:431, 1956.

Journal

Archives of OphthalmologyAmerican Medical Association

Published: Jul 1, 1961

There are no references for this article.